The asymmetric synthesis of (S)-2,6-dimethylchroman-4-one (3) is described. An intramolecular Mitsunobu cyclization to the desired (S)-2,6-dimethylchroman-4-one was employed as the key step.
Introduction
The chroman-4-one (2,3-dihydro-4-oxo-4H-1-benzopyran) ring system occupies an important position among oxygen heterocycles and features in a wide variety of compounds of biological and medicinal interest.
1 It occurs naturally with a variety of substituents at C-2. Examples include the antibiotic LL-D253α (1), 2 the flavanone pinostrobin (2) 3 and the plant product (S)-2,6-dimethylchroman-4-one (3). 4 In addition, many biologically active natural products containing a chroman ring system have been synthesized via 2-substituted chroman-4-one intermediates, including α-tocopherol (vitamin E) (4). 5 Stereocontrolled routes to 2-substituted chromanones are few in number. Successful examples include the diastereoselective conjugate addition of cuprates to homochiral 3-(p-tolyl-Notwithstanding these examples, the preparation and manipulation of substituted chroman-4-ones can be problematic, due in part to the ease with which they undergo racemization via the ring opening equilibrium shown in Scheme 1. 11 With this in mind, we have been evaluating the potential of approaches to 2-substituted chromanones based upon both inter-and intramolecular Mitsunobu reactions. 12 In this paper we describe the application of the Mitsunobu cyclization to the synthesis of (S)-2,6-dimethylchroman-4-one (3), which has been isolated from the essential oil produced by natural roots (and also from genetically transformed root cultures) of Leontopodium alpinum (Edelweiss).
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Results and Discussion
Commercially available ethyl (R)-3-hydroxybutyrate (5) 13 was protected as the TBS ether which was then converted into the Weinreb amide 6 using standard conditions (Scheme 2). 14 Addition of two equivalents of lithium o-lithium-4-methylphenoxide (prepared from 2-bromo-4-methylphenol and two equivalents of n BuLi) to the amide 6 gave the ketone 7 in 74% yield (based on 6). The TBS protecting group was removed by treatment with 10% p-TsOH in aqueous THF and gave the alcohol 8 in 81% yield. Exposure of 8 to Mitsunobu conditions 15 (1 equivalent of triphenylphosphine and diethyl azodicarboxylate in THF at 0 o C) resulted in smooth cyclization to the chromanone (-)-3. A minor by-product was identified as the elimination product 9, 16 which was isolated in 7% yield. The spectral data for our synthetic sample of 3 was similar to the reported data for the natural sample, 4 however, our material was crystalline (as opposed to an oil) with a specific rotation of the correct sign but more than double the magnitude of that reported. (S)-2,6-Dimethylchroman-4-one (3) has also been prepared by Wallace via the diastereoselective conjugate addition of lithium dimethylcuprate to the appropriate 3-(ptolylsulfinyl)chromone. 17 The synthetic material reported by Wallace was also a crystalline solid and had a much higher specific rotation than that reported for the natural product. Since both synthetic approaches resulted in material with similar specific rotations it calls into question the optical purity of the material isolated from the natural source. There are several reasons why natural products of biosynthetic origin might not be enantiomerically pure and these have been discussed elsewhere. 18 Specifically for chroman-4-ones bearing a C-2 stereocenter there is the potential for racemization via the reversible ring opening outlined earlier (Scheme 1), either in vivo or during isolation. In summary, the synthesis of (S)-2,6-dimethylchroman-4-one (3) has been described employing an intramolecular Mitsunobu inversion reaction as the key step. The specific rotation of the synthetic material was larger than that described for the natural product. However, as the specific rotation of a sample prepared by a different synthetic route was also much larger than that of the natural product, the optical purity of the sample obtained from the natural source is called into question.
Experimental Section
General Procedures. Melting points were determined using a Thomas-Hoover capillary melting apparatus and are uncorrected. 
Ethyl (R)-3-(tert-butyldimethylsilyl)oxybutyrate.
To a stirred solution of ethyl-(R)-3-hydroxybutyrate 5 (2.0 g, 15 mmol) and imidazole (1.36 g, 20 mmol) in dichloromethane (75 mL) was added tert-butyldimethylsilyl chloride (2.4 g, 16 mmol). The mixture was stirred at room temperature overnight and the resulting white precipitate was poured into saturated aqueous ammonium chloride (150 mL). The mixture was extracted with dichloromethane (3 x 50 mL) and the combined extracts were washed with water (50 mL), brine (50 mL), dried and evaporated. Flash chromatography of the residue, eluting with hexane -ether (19:1), gave the title compound as a colorless oil (3.28, 89%). Spectral data for this compound matched those previously reported. 
